Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small… Read more
Summit Therapeutics PLC - Asset Resilience Ratio
Summit Therapeutics PLC (SMMT) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Summit Therapeutics PLC's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Summit Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Summit Therapeutics PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Summit Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Summit Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Summit Therapeutics PLC (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Summit Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 70.60% | $307.49 Million | $435.56 Million | +14.02pp |
| 2023-12-31 | 56.57% | $114.82 Million | $202.95 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $664.17 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $78.39 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $76.38 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $46.98 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $35.71 Million | -- |
| 2005-12-31 | 80.01% | $20.70 Million | $25.87 Million | +3.01pp |
| 2004-12-31 | 77.00% | $20.70 Million | $26.88 Million | -- |